Mycophenolate mofetil is an effective and safe option for the management of systemic sclerosis-associated interstitial lung disease: results from the Australian Scleroderma Cohort Study. - Concepedia

Concepedia

Publication | Closed Access

Mycophenolate mofetil is an effective and safe option for the management of systemic sclerosis-associated interstitial lung disease: results from the Australian Scleroderma Cohort Study.

41

Citations

0

References

2017

Year

Claire Owen, Gene‐Siew Ngian, Kathleen Elford, O. Moore, Wendy Stevens, Mandana Nikpour, Candice Rabusa, Susanna Proudman, Janet Roddy, Jane Zochling,

Abstract

In patients with SSc-ILD with declining pulmonary function, MMF therapy was associated with stability for up to 36 months. Early adverse events leading to discontinuation occurred less frequently in patients treated with MMF than in AZA treated patients.